HUTCHMED (HCM) News Today $14.31 -0.30 (-2.05%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's WhyHUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's What HappenedDecember 16, 2024 | marketbeat.comHutchmed announces BTD in China for Orpathys, Tagrisso combinationDecember 12, 2024 | markets.businessinsider.comHUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)December 12, 2024 | finance.yahoo.comHUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)December 12, 2024 | globenewswire.comHUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor TherapyDecember 11, 2024 | globenewswire.comBNP Paribas Financial Markets Sells 132,711 Shares of HUTCHMED (China) Limited (NASDAQ:HCM)BNP Paribas Financial Markets trimmed its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 69.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 58,443 shares of the company's stock after sellDecember 10, 2024 | marketbeat.comInnovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial CancerDecember 3, 2024 | prnewswire.comHUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial CancerDecember 3, 2024 | globenewswire.comHUTCHMED (China) Limited (NASDAQ:HCM) Stake Cut by Bellevue Group AGBellevue Group AG decreased its holdings in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 97.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 24,015 shares of the company's stock afterDecember 2, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down - Should You Sell?HUTCHMED (NASDAQ:HCM) Shares Gap Down - Time to Sell?November 29, 2024 | marketbeat.comHUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current TermsNovember 28, 2024 | markets.businessinsider.comHUTCHMED Announces Renewal Of ORPATHYS Inclusion In China's NRDLNovember 28, 2024 | markets.businessinsider.comHUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current TermsNovember 28, 2024 | globenewswire.comHutchmed to receive milestone payment following Takeda launch of FruzaqlaNovember 22, 2024 | msn.comHUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in JapanNovember 21, 2024 | globenewswire.comHUTCHMED (China) (NASDAQ:HCM) Stock, Option ChainNovember 21, 2024 | benzinga.comHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board CommitteeNovember 20, 2024 | globenewswire.comHUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by M&G PlcM&G Plc raised its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 98.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 267,231 shares of the company's stock after acquiring an additional 132,333 shares during the quarterNovember 9, 2024 | marketbeat.comHUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia CongressNovember 5, 2024 | globenewswire.comHUTCHMED (NASDAQ:HCM) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a research report on Monday.November 4, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - Should You Buy?HUTCHMED (NASDAQ:HCM) Shares Gap Up - Here's WhyNovember 1, 2024 | marketbeat.comHUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by TakedaOctober 31, 2024 | finance.yahoo.comHUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by TakedaOctober 31, 2024 | globenewswire.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume - Here's WhyHUTCHMED (NASDAQ:HCM) Sees Large Volume Increase - What's Next?October 18, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up - What's Next?HUTCHMED (NASDAQ:HCM) Shares Gap Up - Should You Buy?October 16, 2024 | marketbeat.comHUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trialOctober 16, 2024 | globenewswire.comHUTCHMED (NASDAQ:HCM) Stock Price Down 2.3% - Should You Sell?HUTCHMED (NASDAQ:HCM) Shares Down 2.3% - Here's WhyOctober 11, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $20.82HUTCHMED (NASDAQ:HCM) Shares Gap Down to $20.82October 3, 2024 | marketbeat.comRenaissance Technologies LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM)Renaissance Technologies LLC raised its holdings in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 74.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 131,300 shares of the company'October 3, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Sees Strong Trading VolumeHUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading VolumeOctober 2, 2024 | marketbeat.comHUTCHMED (China) Ltd (HCM) Shares Up 2.9% on Oct 2October 2, 2024 | gurufocus.comHUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three yearsOctober 1, 2024 | finance.yahoo.comResearch Analysts Set Expectations for HUTCHMED (China) Limited's FY2025 Earnings (NASDAQ:HCM)HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) - Equities researchers at Trinity Delta increased their FY2025 earnings per share (EPS) estimates for shares of HUTCHMED in a report released on Wednesday, September 25th. Trinity Delta analyst L. Gregorek now expects that the company will postSeptember 30, 2024 | marketbeat.comHUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by TakedaSeptember 24, 2024 | globenewswire.comHUTCHMED (NASDAQ:HCM) Shares Cross Below 50 Day Moving Average of $18.21HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50 Day Moving Average of $18.21September 20, 2024 | marketbeat.comHUTCHMED (HCM) Shares Cross Above 200 DMASeptember 15, 2024 | nasdaq.comHUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Acadian Asset Management LLCAcadian Asset Management LLC cut its stake in HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 20.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 389,115 shares of the company's stock after selling 97,809 shareSeptember 12, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Up to $16.03HUTCHMED (NASDAQ:HCM) Shares Gap Up to $16.03September 11, 2024 | marketbeat.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.29HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.29September 10, 2024 | marketbeat.comHUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung CancerSeptember 8, 2024 | globenewswire.comHUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in ChinaAugust 30, 2024 | markets.businessinsider.comHUTCHMED Withdraws SNDA For Fruquintinib And Paclitaxel Combination In Second-Line Gastric CancerAugust 30, 2024 | markets.businessinsider.comHUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in ChinaAugust 30, 2024 | msn.comHUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in ChinaAugust 30, 2024 | globenewswire.comHUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short SellersAugust 28, 2024 | msn.comHUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.89HUTCHMED (NASDAQ:HCM) Shares Gap Down to $17.89August 23, 2024 | marketbeat.comHUTCHMED to Host Expert Call to discuss Immune ThrombocytopeniaAugust 21, 2024 | globenewswire.comHUTCHMED (China) Limited (NASDAQ:HCM) Sees Large Drop in Short InterestHUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 474,900 shares, a decline of 7.2% from the July 15th total of 511,600 shares. Based on an average daily volume of 145,600 shares, the short-interest ratio is currently 3.3 days.August 19, 2024 | marketbeat.comDDOG Aug 2024 101.000 put (DDOG240823P00101000)August 18, 2024 | finance.yahoo.comHCM Sep 2024 15.000 putAugust 17, 2024 | ca.finance.yahoo.com Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] HCM Media Mentions By Week HCM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HCM News Sentiment▼1.050.61▲Average Medical News Sentiment HCM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HCM Articles This Week▼12▲HCM Articles Average Week Get HUTCHMED News Delivered to You Automatically Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News ITCI News ROIV News ASND News RVMD News LNTH News LEGN News NUVL News BPMC News ELAN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HCM) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HUTCHMED (China) Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share HUTCHMED With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
